Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-May-24 6:24 PM View:  | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 02-May-24 | Conversion | 21,296 | -- | -- | 2% 863.52K to 884.82K | |
| 03-May-24 6:24 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 02-May-24 | Sale (Planned) | 50,000 | $8.47 | $423,500.00 | (6%) 884.82K to 834.82K | |
| 03-May-24 6:24 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 01-May-24 | Gift | 25,000 | -- | -- | (3%) 938.52K to 913.52K | |
| 03-May-24 6:24 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 01-May-24 | Sale (Planned) | 50,000 | $7.73 | $386,500.00 | (5%) 913.52K to 863.52K | |
| 02-May-24 5:41 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 30-Apr-24 | Sale (Planned) | 11,447 | $7.95 | $90,963.60 | (< 1%) 7.23M to 7.22M | |
| 29-Apr-24 6:41 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 25-Apr-24 | Option Exercise | 3,000 | $1.06 | $3,180.00 | < 1% 543.23K to 546.23K | |
| 29-Apr-24 6:41 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 25-Apr-24 | Planned Option Sale | 3,000 | $7.67 | $23,020.50 | (< 1%) 546.23K to 543.23K | |
| 18-Apr-24 5:12 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 17-Apr-24 | Planned Option Sale | 23,124 | $7.58 | $175,349.00 | (2%) 1.25M to 1.23M | |
| 18-Apr-24 5:12 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 17-Apr-24 | Option Exercise | 37,500 | $2.22 | $83,250.00 | 3% 1.22M to 1.25M | |
| 18-Apr-24 5:12 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 16-Apr-24 | Planned Option Sale | 25,000 | $7.67 | $191,658.00 | (2%) 1.24M to 1.22M | |
| 18-Apr-24 5:12 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 16-Apr-24 | Option Exercise | 37,500 | $2.22 | $83,250.00 | 3% 1.2M to 1.24M | |
| 18-Apr-24 5:12 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 16-Apr-24 | Sale (Planned) | 11,447 | $7.66 | $87,725.20 | (< 1%) 7.24M to 7.23M | |
| 05-Apr-24 5:44 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 04-Apr-24 | Sale (Planned) | 40,000 | $9.02 | $360,800.00 | (4%) 1.0M to 963.52K | |
| 05-Apr-24 5:44 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 04-Apr-24 | Conversion | 25,000 | -- | -- | 3% 978.52K to 1.0M | |
| 05-Apr-24 5:44 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 04-Apr-24 | Sale (Planned) | 25,000 | $9.02 | $225,500.00 | (3%) 963.52K to 938.52K | |
| 05-Apr-24 5:44 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 03-Apr-24 | Sale (Planned) | 25,000 | $8.84 | $221,000.00 | (2%) 1.0M to 978.52K | |
| 05-Apr-24 5:44 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 03-Apr-24 | Conversion | 25,000 | -- | -- | 2% 1.04M to 1.07M | |
| 05-Apr-24 5:44 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 03-Apr-24 | Gift | 25,000 | -- | -- | (2%) 1.07M to 1.04M | |
| 05-Apr-24 5:44 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 03-Apr-24 | Sale (Planned) | 40,000 | $8.84 | $353,600.00 | (4%) 1.04M to 1.0M | |
| 03-Apr-24 5:42 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 02-Apr-24 | Sale (Planned) | 11,447 | $8.82 | $100,942.00 | (< 1%) 7.25M to 7.24M | |
| 03-Apr-24 5:43 PM View: | Chavez R Martin Phd Director | Recursion Pharmaceuticals, ... (RXRX) | 01-Apr-24 | Grant | 2,001 | -- | -- | 3% 58.08K to 60.08K | |
| 03-Apr-24 5:43 PM View: | Dar Zavain Director | Recursion Pharmaceuticals, ... (RXRX) | 01-Apr-24 | Grant | 1,467 | -- | -- | 2% 87.59K to 89.06K | |
| 03-Apr-24 5:43 PM View: | Li Dean Y Director | Recursion Pharmaceuticals, ... (RXRX) | 01-Apr-24 | Grant | 1,267 | -- | -- | < 1% 3.17M to 3.17M | |
| 03-Apr-24 5:42 PM View: | Burrell Terry-Ann Director | Recursion Pharmaceuticals, ... (RXRX) | 01-Apr-24 | Grant | 1,467 | -- | -- | 3% 54.85K to 56.31K | |
| 01-Apr-24 6:40 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 28-Mar-24 | Gift | 25,000 | -- | -- | (2%) 1.13M to 1.11M | |
| 01-Apr-24 6:40 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 28-Mar-24 | Sale (Planned) | 40,000 | $10.10 | $404,000.00 | (4%) 1.11M to 1.07M | |
| 01-Apr-24 6:40 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 28-Mar-24 | Sale (Planned) | 25,000 | $10.10 | $252,500.00 | (2%) 1.07M to 1.04M | |
| 01-Apr-24 6:40 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 28-Mar-24 | Conversion | 25,000 | -- | -- | 2% 1.11M to 1.13M | |
| 25-Mar-24 6:39 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 21-Mar-24 | Planned Option Sale | 8,000 | $10.75 | $85,979.90 | (1%) 647.98K to 639.98K | |
| 25-Mar-24 6:39 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 21-Mar-24 | Option Exercise | 8,000 | $1.06 | $8,480.00 | 1% 639.98K to 647.98K | |
| 21-Mar-24 5:38 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 19-Mar-24 | Sale (Planned) | 20,054 | $10.79 | $216,423.00 | (< 1%) 7.27M to 7.25M | |
| 14-Mar-24 7:28 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 13-Mar-24 | Planned Option Sale | 25,000 | $11.03 | $275,815.00 | (2%) 1.23M to 1.2M | |
| 14-Mar-24 7:28 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 13-Mar-24 | Option Exercise | 37,500 | $2.22 | $83,250.00 | 3% 1.19M to 1.23M | |
| 14-Mar-24 7:28 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 12-Mar-24 | Option Exercise | 37,500 | $2.22 | $83,250.00 | 3% 1.18M to 1.22M | |
| 14-Mar-24 7:28 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 12-Mar-24 | Planned Option Sale | 25,000 | $10.45 | $261,375.00 | (2%) 1.22M to 1.19M | |
| 08-Mar-24 7:08 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 06-Mar-24 | Planned Option Sale | 36,319 | $11.86 | $430,682.00 | (3%) 1.17M to 1.13M | |
| 08-Mar-24 7:08 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 06-Mar-24 | Conversion | 10,000 | -- | -- | < 1% 1.1M to 1.11M | |
| 08-Mar-24 7:08 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 06-Mar-24 | Planned Option Sale | 3,605 | $11.55 | $41,648.30 | (< 1%) 1.13M to 1.13M | |
| 08-Mar-24 7:08 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 06-Mar-24 | Conversion | 25,000 | -- | -- | 2% 1.11M to 1.14M | |
| 08-Mar-24 7:08 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 06-Mar-24 | Gift | 10,000 | -- | -- | (< 1%) 1.18M to 1.17M | |
| 08-Mar-24 7:08 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 06-Mar-24 | Option Exercise | 39,924 | $4.42 | $176,384.00 | 4% 1.14M to 1.18M | |
| 08-Mar-24 7:08 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 06-Mar-24 | Sale (Planned) | 21,395 | $11.55 | $247,175.00 | (2%) 1.13M to 1.11M | |
| 07-Mar-24 6:53 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 05-Mar-24 | Sale (Planned) | 20,054 | $12.06 | $241,805.00 | (< 1%) 7.29M to 7.27M | |
| 23-Feb-24 7:22 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 22-Feb-24 | Option Exercise | 8,000 | $1.06 | $8,480.00 | 1% 639.98K to 647.98K | |
| 23-Feb-24 7:22 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 22-Feb-24 | Planned Option Sale | 8,000 | $14.90 | $119,160.00 | (1%) 647.98K to 639.98K | |
| 21-Feb-24 5:37 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 20-Feb-24 | Sale (Planned) | 20,054 | $12.32 | $247,125.00 | (< 1%) 7.31M to 7.29M | |
| 16-Feb-24 7:57 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 15-Feb-24 | Payment of Exercise | 11,148 | $12.43 | $138,570.00 | (< 1%) 1.12M to 1.1M | |
| 16-Feb-24 7:59 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 15-Feb-24 | Payment of Exercise | 7,172 | $12.43 | $89,148.00 | (< 1%) 1.19M to 1.18M | |
| 16-Feb-24 7:58 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 15-Feb-24 | Payment of Exercise | 5,379 | $12.43 | $66,861.00 | (< 1%) 645.36K to 639.98K | |
| 15-Feb-24 6:00 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 14-Feb-24 | Option Exercise | 37,500 | $2.22 | $83,250.00 | 3% 1.17M to 1.21M |
